A multinational phase IIb/III trial of beraprost sodium, an orally active prostacyclin analogue, in patients with primary glomerular disease or nephrosclerosis (CASSIOPEIR trial), rationale and study design

Hidetomo Nakamoto¹*, Toshiro Fujita², Hideki Origasa³, Masanao Isano⁴, Hajimu Kurumatani⁴, Kiyonobu Okada⁴, Hiroyuki Kanoh⁵, Takashi Kiriyama⁵ and Shunsuke Yamada⁵

Abstract

Background: Chronic kidney disease (CKD) is public health concern even in Asian countries. TRK-100STP, a sustained release tablet of an orally-active prostacyclin analogue, beraprost sodium, is suggested to suppress worsening of some parameters of renal filtration function, containing in slope of 1/serum creatinine (1/SCr) vs. time in a phase II clinical trial.

Methods/design: We describe the design of the phase IIb/III trial of TRK-100STP, CASSIOPEIR (CRF Asian Study with Oral PGI2 derivative for Evaluating Improvement of Renal function) conducted in approximately 160 centers in China, Hong Kong, Japan, Malaysia, Republic of Korea, Taiwan, and Thailand. A total of 750 patients (n = 250 per group) with primary glomerular disease or nephrosclerosis were planned to be enrolled. Patients were randomized into one of three treatment groups in a double-blind, placebo-controlled manner: TRK-100STP 60 μg b.i.d.; TRK-100STP 120 μg b.i.d.; or placebo. The treatment period is planned to last 2 to 4 years. The primary efficacy endpoint is the renal composite endpoint including doubling of SCr and ESRD (dialysis induction, renal transplantation, or increase in SCr to ≥6.0 mg/dL).

Discussion: This trial targeting CKD patients is designed to (a) demonstrate the superiority of TRK-100STP over placebo using renal composite endpoints, (b) determine the recommended clinical dose, and (c) assess the safety of TRK-100STP in this population and setting.

Trial registration: ClinicalTrials.gov Identifier: NCT01090037.

Keywords: Prostacyclin analogue, PGI2, Beraprost sodium, Chronic kidney disease, Primary glomerular disease, Nephrosclerosis, Serum creatinine, Renal composite endpoint, CASSIOPEIR, TRK-100STP

Background

The number of patients with end-stage renal disease (ESRD) requiring dialysis or renal transplantation has increased globally in recent years. Among the primary diseases that lead to ESRD are the primary and secondary glomerular diseases such as diabetic nephropathy and tubulointerstitial nephritis.

Primary glomerular diseases and nephrosclerosis still comprise a significant proportion of chronic kidney disease (CKD) patients. Primary glomerular diseases are especially important causes for the need for dialysis in Asian countries. They are currently the most frequent causes in China [1] and the second in most other Asian countries [2-4]. Nephrosclerosis is the third frequent cause in most Asian countries and has been increasing [1-5].

The primary care of CKD treatment is to delay renal function deterioration. Current treatments include dietary...
restriction and antihypertensive drug therapy. Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin-II receptor blockers (ARBs), which are often administered to both diabetic nephropathy and non-diabetic CKD patients, have been established as the recommended treatment agents for non-diabetic nephropathy patients [6], although either ACEIs or ARBs are insufficient for the prevention of progressive renal disease. Therefore, an additional treatment that is able to significantly delay the progression of CKD is highly coveted.

To meet this unmet medical need, clinical trials have been conducted attempting to delay CKD progression with combination therapies using renin-angiotensin system (RAS) inhibitors. Unfortunately, these trials failed to show an improvement in efficacy with composite renal endpoints while adverse events increase in some of them. Clinical benefits of combination treatments with multiple RAS inhibitors are therefore unproven, at least for diabetic nephropathy [7-10].

Furthermore, a recent trial of Nrf2-activating bardoxolone methyl in diabetic nephropathy patients (BEACON) was prematurely terminated due to safety concerns [11]. A trial of an orally administered activated carbon preparation (AST120: Kremezin®), which is currently used in clinical practice for chronic renal failure in Japan, Republic of Korea and Taiwan, also failed to meet the efficacy endpoints in composite renal endpoint in the large EPPIC randomized controlled trials [12]. The development of a novel CKD treatment strategy is therefore increasingly needed.

Beraprost sodium (BPS) is a stable orally-active prostacyclin (PGI2) analogue discovered by Toray Industries, Inc. to overcome instability of prostacyclin in vivo [13]. BPS has a novel mechanism for suppressing the progression of CKD. This treatment also targets renal hypoxia, reflecting a growing body of evidence implicating this as a valid therapeutic approach [14]. BPS has been found to be effective in various animal models of renal disorders [15-19]. In addition, BPS immediate-release tablets prevented the decrease in renal blood flow and function in patients with chronic renal failure [20,21].

Using sustained release tablets of BPS (TRK-100STP), a randomized double-blind placebo-controlled comparative phase II trial aiming to determine the optimal clinical dose was conducted from 2005 to 2008 in Japanese patients with primary glomerular disease or nephrosclerosis as the primary disease [22]. In this trial, serum creatinine (Scr) values were 1.5 to 4.5 for male and 1.3 to 4.0 for female at the initiation of treatment. Randomized patients received oral TRK-100STP 120 μg/day (60 μg b.i.d.), 240 μg/day (120 μg b.i.d.) or placebo for 28 weeks after the 22-week run-in period. The primary endpoint was the difference in slope of 1/Scr vs. time between the run-in period and the treatment period. No statistical difference in the primary endpoint was found between the high-dose (240 μg) group and the placebo group and so a clinical dose recommendation was not determined. Both treatment groups showed better outcomes than the placebo group, with the low-dose (120 μg/day) group showing the highest efficacy. Both active dose groups showed similar effectiveness for additional efficacy endpoints including creatinine clearance, SCr ratio and serum cystatin C, compared to those of the placebo group.

A subgroup analysis was also conducted in the same study among patients with SCr 2.0 mg/dL or higher, whose renal function deterioration was considered irreversible [23]. Deteriorations in all the representative renal filtration functions (i.e. difference in the slope of the 1/SCr vs. time between the run-in period and the treatment period, SCr ratio, serum cystatin C and eGFR) were suppressed in the treatment groups and significant suppressions have been observed in some of these parameters. On the other hand, no clinically relevant safety issues were observed.

Based on these results, it was judged that a hypothesis could be set up to be verified in the phase IIb/III trial. The clinically recommended dose is to be re-evaluated using the same doses as ones in the phase II trial.

This paper details the design and methodology of a phase IIb/III trial (CASSIOPEIR: CRF Asian Study with Oral PGI2 derivative for Evaluating Improvement of Renal function) conceived on the basis of the evidence and findings mentioned above in order to investigate whether TRK-100STP is superior to placebo in treating patients with primary glomerular disease or nephrosclerosis. Evaluating composite renal endpoints, the trial aims also to determine a recommended therapeutic dose of TRK-100STP.

Methods/design

Aim of trial

This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group comparative trial targeting CKD patients designed to: (a) demonstrate the superiority of TRK-100STP over placebo using renal composite endpoints, including the extension of the time to the start of dialysis treatment; (b) determine the recommended clinical dose by comparing the low-dose (120 μg/day), high-dose (240 μg/day), and placebo groups; and (c) assess the safety of TRK-100STP in this population and setting.

Study design

The trial is being conducted in approximately 160 sites, including centers in China, Hong Kong, Japan, Malaysia, Republic of Korea, Taiwan and Thailand. The protocol has been approved by the Ethics Review Committee/Institutional Review Board affiliated with each center.
The trial is being conducted in accordance with Good Clinical Practice, and Declaration of Helsinki. All patients provided written informed consent. The trial has been registered on ClinicalTrials.gov, NCT01090037.

A total of 750 patients (n = 250 per group) with primary glomerular disease or nephrosclerosis are planned to be randomized. The rationale for setting the sample size at 250 subjects per group is based on “data handling procedure #2: 3-month lag censoring analysis” as follows. In the event of doubling of SCr or increase in SCr to $\geq 6.0$ mg/dL, the 2.5-year event rate estimated from subjects with SCr $\geq 2.0$ mg/dL that were enrolled in the last phase II trial was 48% for the placebo group and 33% for 240 $\mu$g group. Therefore, assuming a 2-year-enrollment period, a 2-year follow-up period, and a 35% dropout rate at 2.5 years for each group, the number of subjects required per group is estimated at 237 (with two-sided 5% significance level and 90% statistical power). For all subjects, placebo was orally administered for 2 to 8 weeks, twice a day, during the run-in period, when subjects were blinded although investigators recognized that subjects received placebo (Figure 1). Prohibited and restricted concomitant medications are detailed in Table 1. Subjects who met the inclusion and exclusion criteria (summarized in Table S2; see Additional file 1) after 2-to-8-week run-in period were randomized into one of three treatment groups for the 2-to-4-year treatment period in a double-blind manner: TRK-100STP 120 $\mu$g; TRK-100STP 240 $\mu$g; or placebo. Subjects randomized in the 240 $\mu$gd o s eg ro u ps t a r t e dw i t ha d a i l yd o s eo f1 2 0 $\mu$g for 2 weeks and was then increased to 240 $\mu$g/day. While the treatment period was planned to last for 2 to 4 years, this may be extended if the incidence of renal composite endpoint is smaller than expected.

Study endpoints
The primary efficacy endpoint for the trial is the renal composite endpoint (time to first occurrence of one of the following events): 1) Doubling of SCr; defined as at least a two-fold increase in SCr during the treatment period over the baseline value during the run-in period (mean value of the last two measurement results during the run-in period); and 2) ESRD (occurrence of any of the following: introduction of dialysis, renal transplantation, or increase in SCr to $\geq 6.0$ mg/dL). With regards to the doubling of SCr, and the increase in SCr to $\geq 6.0$ mg/dL, a re-confirmation will be performed with blood sample collection and measurement four or more weeks after the initial date on which these endpoints were confirmed, and once reconfirmed, the initial date will be judged as the date on which these renal composite endpoints are reached. The clinical trial and administration of the study drug will be continued for the subject even after the confirmation that SCr has doubled or increased to $\geq 6.0$ mg/dL until introduction of dialysis or renal transplantation is deemed necessary. If the administration of the study drug is prematurely discontinued during the treatment period, the clinical study will be continued as an efficacy follow-up until introduction of dialysis or renal transplantation is judged to be needed.

Secondary endpoints are as follows: 1) Renal composite endpoint or death (from any causes); 2) doubling of SCr; 3) ESRD; 4) introduction of dialysis; 5) renal transplantation; 6) increase in SCr to $\geq 6.0$ mg/dL; 7) slope of 1/SCr vs. time; and 8) eGFR. In addition, the safety endpoints include adverse events, laboratory tests, vital signs and body weight, and 12-lead electrocardiogram (ECG). Also to be evaluated are miscellaneous efficacy endpoints such as “cardiovascular events or renal composite endpoints”.

All SCr values used for analysis of the endpoints are measured at the central clinical laboratory.
### Analysis set

The full analysis set (FAS) will consist of subjects taking at least one dose of study drug for the treatment period. However, subjects meeting the following descriptions are excluded from the FAS:

1. Subjects providing no data after administration of the study drug for the treatment period;
2. Subjects found not to fulfill the inclusion criterion (2) or (3);
3. Subjects found to meet the exclusion criterion (1), (2), or (6).

Subjects who satisfy all of the following criteria out of FAS constitute the per protocol set (PPS), and are:

1. Subjects meeting the inclusion criteria;
2. Subjects not meeting the exclusion criteria;
3. Subjects providing three or more SCr measurement data points obtained at and after Week 4 of the treatment period (including at least one data point taken at Day 70 of the treatment period or later);
4. Subjects whose drug compliance rate is two-thirds or higher during the administration period of the study drug for the treatment period.

The safety analysis set (SAF) will include subjects taking at least one dose of the study drug for the treatment period.

The pharmacokinetics analysis set (PKAS) is defined by subjects fulfilling all of the following criteria:

1. Subjects taking at least one dose of the study drug for the treatment period;
2. Subjects providing at least one data point (sample) for plasma BPS concentration determination for which information on the date and time of blood collection and medication before the collection is available.

### Handling of data

For efficacy assessment, the following three types of data handling processes have been established:

1. **Data Handling Procedure #1**
   - All data will be adopted for analysis that is obtained after the start of the administration of the study drug for the treatment period (Intension-To-Treat (ITT) analysis).

2. **Data Handling Procedure #2**
   - For subjects who discontinue the administration of the study drug for the treatment period, their data obtained after 3 months following the discontinuation will not be used, and data collection for them is censored at 3 months from the discontinuation or at completion of the study, whichever comes first (3-month lag censoring analysis).

3. **Data Handling Procedure #3**
   - Subjects that take a prohibited concomitant medication will be censored at the time of the medication. Subjects will be censored at any time when they stop taking the study drug for the treatment period, for whatever reason.

### Analysis of efficacy

The primary population for efficacy analysis will be the FAS, and the data will be processed according to the Data Handling Procedure #1. Similar analyses will be conducted according to the Data Handling Procedure #2 in terms of FAS and according to the Data Handling Procedure #3 in terms of PPS. Statistical testing will use two-sided 5% significance level and calculate two-sided 95% confidence interval, unless otherwise specified.

### Analysis of safety

Vital signs, adverse events, laboratory tests, body weight, 12-lead electrocardiogram (ECG) and pregnancy test will be performed for the purpose of safety evaluation.

### Table 1 Prohibited and restricted concomitant medications

| Prohibited Concomitant Medications | The following medications are prohibited for use during the study period. |
|-----------------------------------|-------------------------------------------------------------------------|
|                                   | (1) Prostaglandin drugs except for ophthalmic solutions and ointments.  |
|                                   | (2) Fluorinated pyrimidine antifungal agents.                          |

| Restricted Concomitant Medications | (1) For ACEIs and ARBs, changing the dose or introducing the medication is not permitted from the obtaining of informed consent to the end of the study drug administration. Antihypertensive drugs other than ACEIs or ARBs are permitted to be used. |
|-----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                   | (2) From obtaining of informed consent to the end of the study drug administration, changing the dose or introducing the medication is not permitted for pentoxifylline, dilazep hydrochloride, or dipyridamole. |
|                                   | (3) From obtaining of informed consent to the end of the study drug administration, NSAIDs are not permitted to be taken for more than four consecutive weeks; and during the week prior to a visit, NSAIDs are not permitted to be taken. |
**Results**

The first patient was enrolled in this trial in June 8, 2010. A total of 1105 subjects were enrolled in run-in period. From July 8, 2010 through April 26, 2012 a total of 892 subjects underwent randomization (200 in China, 13 in Hong Kong, 339 in Japan, 46 in Malaysia, 135 in Republic of Korea, 108 in Taiwan and 51 in Thailand).

The EJC and DSMB have been conducted 2 and 3 times to date, respectively and have concluded that there is no concern regarding the continuation of this trial.

**Discussion**

This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group comparative trial targeting CKD patients designed to, (a) demonstrate the superiority of TRK-100STP over placebo using renal composite endpoints, (b) determine the recommended clinical dose, which was not established following the respective phase II trial, and (c) assess the safety of TRK-100STP in this population and setting.

Prostacyclin, which was discovered in 1976, was expected to be a key advance for novel pharmacotherapy for various cardiovascular diseases [24]. However, prostacyclin proved to be an unstable chemical substance having a short elimination half-life in blood plasma. The clinical use of prostacyclin was consequently limited to serious cases of pulmonary arterial hypertension (PAH) for which 24-hour continuous infusion is indicated [25]. BPS is a stable orally-active prostacyclin analogue and its immediate-release tablet obtained manufacturing approval for the treatment of chronic arterial occlusive diseases from the Japanese regulatory agency in January 1992 (brand names: Dornar® and Procylin®). An additional indication for primary pulmonary hypertension was approved in September 1999. Besides Japan, BPS immediate-release tablets were launched in other Asian markets including China, Indonesia, Republic of Korea, Thailand and The Philippines, between 1997 and 2006.

TRK-100STP, a hydrogel-forming matrix preparation, provides a sustained-release preparation of BPS [26]. In October 2007, TRK-100STP was given marketing approval in Japan for the treatment of PAH with a maximum daily dose of 360 μg (180 μg b.i.d.) (Brand names: Careload® and Berasus®). The maximum daily clinical dose of TRK-100STP has doubled those of the immediate-release tablet for the indication of pulmonary hypertension in Japan.

BPS has the same pharmacological actions as those of natural prostacyclin, including anti-platelet and vasodilating effects [27], as well as being able to protect vascular endothelial cells [28] and inhibit inflammatory cytokines production including MCP-1 [17].

The importance of tubulointerstitial hypoxia has recently been highlighted as the final common pathway of CKD [29], a notion supported by an increasing body of evidence from animal models [14,30,31] and clinical study [32]. Renal blood flow is reduced when renal glomeruli are damaged by pathological factors such as inflammation and hypertension. Lack of oxygen, particularly in the tubulointerstitium of the outer-medullary region which is susceptible to hypoxia, triggers further damage to renal glomeruli which causes renal function to progressively decline [33]. It has been demonstrated, in the glomerular nephritis rat model, that the beneficial effects of BPS are attributed, at least in part, to the amelioration of tubulointerstitial hypoxia [19].
Prostacyclin is a vasodilator which, at a high dose, diminishes blood pressure or brings about increased heart rate (HR) as compensation in several animal species [27]. However, neither increased HR nor lower blood pressure is observed at the clinical dose up to 180 μg b.i.d. in patients with PAH [34]. Additionally, the phase II trial of CKD patients demonstrated that TRK-100STP up to 120 μg b.i.d. does not affect either blood pressure or urinary protein. Thus the effect of BPS to suppress the reduction of renal function is not related to blood pressure lowering or to reducing urinary protein levels. This suggests that the mechanism of beneficial effect of BPS for renal function is different from that of ACEIs/ARBs. Other features of this trial are as follows:

1) Treatment with TRK-100STP is employed, in principle, as an add-on to existing treatments. No limitation was set against concomitant ACEIs/ARBs use, although dose alternation and newly initiated prescription is restricted. Meanwhile recent evidence from large-scale clinical studies indicates that combination therapy with RAS inhibitors is not effective and also increases certain safety concerns in some of them. The add-on approach was therefore chosen in this trial, based on the observation that a new approach is required beyond RAS inhibitor-based combination therapy.

2) This trial utilizes carefully defined eligibility criteria that allows for sufficient numbers of events while excluding slow-progressing patients. This is important because the pace of renal function deterioration varies widely among patients, especially among non-diabetic CKD patients where disease progression is sometimes very slow. Enrollment is limited to patients with SCr of 2 mg/dL or higher where an irreversible decrease in renal function is reported [23]. Clinical benefits were more clearly apparent in such patients in the previous phase II trial [22]. Participants must also have experienced progression in renal function deterioration, assessed by the slope of 1/SCr vs. time, within one year before the start of the study. These aspects of recruitment may subsequently help us define the target population likely to benefit most from intervention.

3) The necessity of introduction of dialyses or kidney transplants were determined by the principal investigator based on medical need assessment. All endpoints including the dates of introduction of dialyses or kidney transplants, as well as cardiovascular event occurrence, were validated by an EJC whose members are third-party physicians.

4) Patients with diabetes at pre-enrollment were excluded. The findings of several animal model studies have indicated that BPS may be effective against diabetic nephropathy [35-37]. Researchers have also reported that BPS was effective in patients with microalbuminuria [38]. However, there are several methodological difficulties in covering both diabetic and non-diabetic CKD in a single study protocol. In addition, considering there is a great unmet need for non-diabetic nephropathy treatment in Asia, we decided to prioritize and focus on non-diabetic CKD, wherein renal disorders are not modified by diabetes. As it is difficult in practice to definitively distinguish between patients with diabetic nephropathy and non-diabetic CKD patients with diabetes, all patients with diabetes at pre-enrollment are excluded.

In the original trial design, handling of primary data was stipulated as “3-month lag censoring analysis”. However, Japanese regulatory authority, Pharmaceuticals and Medical Devices Agency (PMDA), advised that ITT analysis should be primary analysis. The priority order of data handling was therefore amended based on the PMDA’s advice. Meanwhile, the sample size estimation and rationale for setting the sample size in “study design”, which was designed based on 3-month lag censoring analysis, was not amended.

Conclusion
This trial evaluates the efficacy and safety of TRK-100STP in the treatment of patients with primary glomerular disease or nephrosclerosis using renal composite endpoints, and also aims to establish a recommended dose of TRK-100STP to optimize clinical outcomes.

Endpoint judgment committee members
Akira Hishida (Chair), Enyu Imai, Masato Nakamura

Data and safety monitoring board members
Akira Saito (Chair), Masaki Kobayashi, Naoki Kashihara

Ethical approval
This trial has been approved by competent regulatory authorities of China, Hong Kong, Japan, Malaysia, Republic of Korea, Taiwan and Thailand. In accordance with the laws of each country, the trial has been conducted after obtaining documented approval from Institutional Review Board/Independent Ethics Committee in each site according to ICH-GCP guidelines.

Additional file

Additional file 1: Table S2. Study inclusion and exclusion criteria.

Competing interests
This trial was funded by Toray Industries, Inc. and Astellas Pharma Inc. HN serves as consultant for Toray. TF is a recipient of research funding and/or consultant for Astellas, Toray, Boehringer Ingelheim, Chugai, Fukuda Denshi, Kyowa Hakko Kirin, Mitsubishi Tanabe, Mochida, Omron, Pfizer and Takeda.
HO serves as a consultant for Toray. MI, HAKU and KO are employees of Toray, while HKA, TK and SY are employees of Astellas.

Authors’ contributions
HN, TF and HAKU participated in the design of the study and wrote the draft of the report. HO participated in the design of the study and provided statistical support. MI, HKA, TK and SY served as study statistician and participated in the design of the study. All authors critically reviewed and approved the manuscript.

Acknowledgements
Masahiko Aki, Kazuhiro Kobayashi, Takeshi Matsuugi, Akio Mori, Yoshitaka Mori of Toray provided assistance on the design of the protocol. Midori Ogasawara of Toray provided assistance on the preparation of the protocol and report. Satoshi Henmi of Toray, Hiroshi Kaku, Tomohisa Kawasaki and Hiroaki Okumura of Astellas and Jun Kishi of MEDCORE ASSOCIATES Inc., provided assistance on the preparation of the report.

Author details
1Department of General Internal Medicine, Saitama Medical University, 38 Morohonono, Moroyamamachi, Iruma-gun, Saitama 350-0495, Japan. 2Division of Clinical Epigenetics, Research Center for Advanced Science and Technology, The University of Tokyo, 4-6-1 Komaba, Meguro-ku, Tokyo 153-8904, Japan. 3Division of Biostatistics and Clinical Epidemiology, Graduate School of Medicine and Pharmaceutical Sciences, The University of Toyama, 2630 Sugitani, Toyama city 930-0194, Japan. 4Toray Industries, Inc, Nihonbashi Mitsui Tower, 1-1, Nihonbashi-Muramachi 2-chome, Chuo-ku, Tokyo 103-8666, Japan. 5Astellas Pharma Inc, 2-5-1 Nihonbashi-honcho, Chuo-ku, Tokyo 103-8411, Japan.

Received: 20 May 2014 Accepted: 28 August 2014 Published: 19 September 2014

References
1. Xie Y, Chen X: Epidemiology, major outcomes, risk factors, prevention and management of chronic kidney disease in China. Am J Nephrol 2008, 28(1):1–7.
2. Akizawa T: Current Status of Dialysis Therapy and Related Clinical Guidelines in Japan. JMA 2010, 353(158):1–87.
3. Hwang SJ: Epidemiology, impact and preventive care of chronic kidney disease in Taiwan. Nephrology (Carlton) 2010, 15(Suppl 2):1–9.
4. Jha V: Current status of chronic kidney disease care in southeast Asia. Semin Nephrol 2009, 29(3):487–496.
5. Jin DC: Current status of dialysis therapy in Korea. Korean J Intern Med 2011, 26(2):133–141.
6. KDIGO: KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kid Int 2013, 81(1–150).
7. Investigators ONTARGET, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C: Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008, 358(15):1547–1559.
8. Imai E, Chan JC, Ko S, Yamazaki T, Kobayashi F, Haneda M, Makino H, ORENT: study investigators: Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. Diabetologia 2011, 54(12):2797–2806.
9. Fried LF, Emanuelli N, Zhang JH, Brophy M, Conner TA, Duxworth W, Leehey DJ, McCullough PA, O’Connor T, PaleyDV, Reilly RF, Seliger SL, Warren SR, Watinck S, Peduzzi P, Guarino P, VA NEPHRON-D Investigators: Combined Angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013, 369(20):1892–1903.
10. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Hoffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pleffer MA, ALTITUDE Investigators: Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012, 367(23):2204–2213.
11. de Zeeuw D, Akizawa T, Audhya P, Bakris GL, Chin M, Christ-Schmidt H, Goldsberry A, Houser M, Krauth M, Lambers Heerspink HJ, McMurray JJ, Meyer CJ, Parving HH, Remuzzi G, Toto RD, Vaziri ND, Warner C, Wittes J, Wroldstad D, Chertow GM, BEACON Trial Investigators: Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med 2013, 369(26):2492–2503.
12. Schulum G, Berl T, Beck G, Remuzzi G, Ritz E: EPPIC (Evaluating Prevention of Progression In Chronic Kidney Disease): Results from phase III, Randomized, Placebo-controlled, double blind trials of AST-120 in adults with CKD. J Am Soc Nephrol 2013, 24:78.
13. Chino K, Nagase H, Matsumoto K, Nishiyama H, Nishio S: Stereoselective synthesis of 5,6-trinor-4R,8R-inter-m-phenylene-PG12 derivatives and their inhibitory activities to human platelet aggregation. Adv Prostaglandin Thromboxane LeukotRes 1985, 15:279–281.
14. Nakagaki M: Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol 2006, 17(1):17–25.
15. Utsunomiya Y, Ogura M, Kawaiura T, Matarai T, Maruyama N, Sakai O: Attenuation of immune complex nephritis in NZB/WF1 mice by a prostacyclin analogue. Clin Exp Immunol 1995, 99(3):454–460.
16. Kurohashi M, Shikata K, Sugimoto H, Shikata Y, Miyake N, Wada J, Miyazaki M, Makino H: Therapeutic effects of prostacyclin analog on crescentic glomerulonephritis of rat. Kidney Int 1998, 53(3):1314–1320.
17. Yamada M, Saaili K, Sato N, Suzuki M, Tamura M, Matsuhashi T, Kurumatani H: Amelioration by beraprost sodium, a prostacyclin analogue, of established renal dysfunction in rat glomerulonephritis model. Eur J Pharmacol 2002, 449(1–2):167–176.
18. Yamaguchi S, Inada C, Tamura M, Sato N, Yamada M, Itaba S, Okazaki S, Matsuura H, Fujii S, Matsuwa F, Goto Y, Mochizuki H, Kurumatani H, Miyamoto M: Beraprost sodium improves survival rates in anti-glomerular basement membrane glomerulonephritis and S/E nephrectomized chronic kidney disease rats. Eur J Pharmacol 2013, 714(1):323–325.
19. Yamaguchi S, Goto Y, Sato N, Kurumatani H, Miyamoto M, Yamada M: Beraprost Sodium Suppresses Progression of Chronic Renal Failure by Protecting Renal Capillary Endothelial Cells and Improving Renal Hypoxia in Glomerulonephritis Rats. J Am Soc Nephrol 2013, 24:886A.
20. Fujita T, Fuke Y, Saito Y, Hikida H, Ohnawa I, Irido M, Komatsu K, Oh H: PGI2 analogue mitigates the progression rate of renal dysfunction improving renal blood flow without glomerular hyperfiltration in patients with chronic renal insufficiency. Prostaglandins Leukot Essent Fatty Acids 2001, 65(4):223–227.
21. Ishida A, Hotta O, Takuma T: Clinical efficacy of PGI2 derivative (BPS) in patients with progressive renal disease. Jpn J Nephrol 2003, 45(3):276.
22. Fujita T, Koyama A, Gejo F, Origasa H, Isono M, Kiryama T: Sustained-release tablets of orally-active prostacyclin analogue, beraprost sodium, for patients with non-diabetic chronic renal failure. J Am Soc Nephrol 2011, 22:247A.
23. Tomino Y: Point of no return in IgA nephropathy. In: study research on progressive renal disorder. Research on measures for intractable diseases. Health and Labour Sciences Research Grants. Comprehensive report and individual reports about each shared in 2003 fiscal year. 2004:167–172.
24. Moncada S, Gryglewski R, Bunting S, Vane JR: An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976, 263:663–665.
25. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapsco NF, Bourdeau WC, Brundage BH, Koerner SK, Langleben D, Keller CA, Murali S, Uretsky BF, Clayton LM, Jöbsis MM, Blackburn SD, Crow MT, Primary Pulmonary Hypertension Study Group: The in vitro and ex vivo antiplatelet effect of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996, 334:296–301.
26. Kurumatani H: Pharmacological profiles and clinical effects of oral sustained release beraprost sodium (Careload LA tablets 60 µg, Beraus LA tablets 60 µg). Nihon Yakugaku Zasshi 2009, 130(2):101–111.
27. Nishio S, Matsuura H, Kanai N: The in vitro and ex vivo antiplatelet effect of TRK-100, a stable prostacyclin analog, in several species. Jpn J Pharmacol 1988, 47:1–10.
28. Sakai A, Yajima M, Nishio S: Cytoprotective effect of TRK-100, a prostacyclin analogue, against chemical injuries in cultured human vascular endothelial cells. Life Sci 1990, 47(8):711–719.
29. Nishio S, Matsuura H, Kanai N: The in vitro and ex vivo antiplatelet effect of TRK-100, a stable prostacyclin analog, in several species. Jpn J Pharmacol 1988, 47:1–10.
30. Fine LG, Bandyopadhay D, Norman JT: Is there a common mechanism for the progression of different types of renal diseases other than proteinuria? Towards the unifying theme of chronic hypoxia. Kidney Int Suppl 2000, 75:522–528.
30. Eckardt KU, Bernhardt WM, Weidemann A, Warnecke C, Rosenberger C, Wesener MS, Willam C. Role of hypoxia in the pathogenesis of renal disease. Kidney Int Suppl 2005, 99:S46–S51.

31. Kang DH, Kanellis J, Hugo C, Truong L, Anderson S, Kerjaschki D, Schreiner GF, Johnson RJ. Role of the microvascular endothelium in progressive renal disease. J Am Soc Nephrol 2002, 13(3):806–816.

32. Inoue T, Kozawa E, Okada H, Inukai K, Watanabe S, Kikuta T, Watanabe Y, Takenaka T, Katayama S, Tanaka J, Suzuki H. Noninvasive evaluation of kidney hypoxia and fibrosis using magnetic resonance imaging. J Am Soc Nephrol 2011, 22(8):1429–1434.

33. Mimura I, Nangaku M. The suffocating kidney: tubulointerstitial hypoxia in end-stage renal disease. Nat Rev Nephrol 2010, 6(11):667–678.

34. Kunieda T, Nakanishi N, Matsubara H, Ohe T, Okano Y, Kondo H, Nishimura M, Shirato K, Tanabe N, Homma S, Yoshida S, Inokuma S, Kodama M, Koike T, Hishida H. Effects of long-acting beraprost sodium (TRK-1005TP) in Japanese patients with pulmonary arterial hypertension. Int Heart J 2009, 50(4):513–529.

35. Wang LN, Tang Z, Shou I, Fukui M, Tomino Y. Effects of the PGI2 analog beraprost sodium on glomerular prostanoid synthesis in rats with streptozotocin-induced diabetes. Nephron 1996, 73(4):637–643.

36. Watanabe M, Nakashima H, Mochizuki S, Abe Y, Ishimura A, Ito K, Fukushima T, Miyake K, Oghara S, Saito T. Amelioration of diabetic nephropathy in OLETF rats by prostaglandin I2 analog, beraprost sodium. Am J Nephrol 2009, 30(1):1–11.

37. Sato N, Kaneko M, Tamura M, Kurumatani H. The prostacyclin analog beraprost sodium ameliorates characteristics of metabolic syndrome in obese Zucker (fatty) rats. Diabetes 2010, 59(4):1092–1100.

38. Owada A, Suda S, Hata T. Effect of long-term administration of prostaglandin I2 in incipient diabetic nephropathy. Nephron 2002, 92(4):788–796.

doi:10.1186/1477-2369-15-153
Cite this article as: Nakamoto et al: A multinational phase IIb/III trial of beraprost sodium, an orally active prostacyclin analogue, in patients with primary glomerular disease or nephrosclerosis (CASSIOPEIR trial), rationale and study design. BMC Nephrology 2014 15:153.